To assess the safety and tolerability of daily oral doses of AMG 073 for 6 weeks in subjects with primary hyperparathyroidism. To assess the clinical effects of AMG 073 by evaluating changes in plasma intact parathyroid hormone (PTH), total serum calcium and calcitonin concentrations, serum bone-specific alkaline phosphatase and urinary N-telopeptide/creatinine ratio. To characterize the pharmacokinetics of AMG 073 in subjects with primary hyperparathyroidism.
Showing the most recent 10 out of 767 publications